CD40LG and melanoma: Using 4-1BBL-CD40L as a trans acting duokine or 4-1BBL-CD27L as a cis acting duokine, Fellermeier-Kopf and colleagues showed that both molecules could induce anti-tumor immunity in a pre-clinical melanoma model in combination with a TCR targeting bispecific antibody (169).